Hepatitis Associated Severe Aplastic Anemia in Children

Madhav Marathe, Sarita Verma, Snehavardhan Pandey, Kannan SubramanianThe Indian Journal of Pediatrics 2025 · DOI · OpenAlex

TL;DR

This case series explores Hepatitis-Associated Severe Aplastic Anemia (HAAA) in a cohort of seven children, highlighting a successful treatment strategy using Intravenous Immunoglobulin (IVIg) as a cost-effective alternative to the standard Anti-Thymocyte Globulin (ATG). The study underscores the potential of whole-exome sequencing to identify genetic predispositions and demonstrates that high survival rates are achievable even in resource-limited clinical settings.

What Problem Does This Paper Address?

Hepatitis-Associated Aplastic Anemia (HAAA) is a rare but life-threatening syndrome where a patient develops bone marrow failure (aplastic anemia) following an acute episode of hepatitis. In most cases, the underlying cause of the initial liver inflammation remains unknown (idiopathic).

The standard of care typically involves intensive immunosuppressive therapy using Anti-Thymocyte Globulin (ATG) or hematopoietic stem cell transplantation. However, ATG is prohibitively expensive in many regions. This paper addresses the clinical profile of HAAA in pediatric patients and evaluates the effectiveness of a modified treatment regimen—utilizing IVIg instead of ATG—within a resource-constrained environment.

Methods

The authors conducted a retrospective case series of seven children diagnosed with HAAA over a 28-month period at a medical center in Pune, India. Their methodology included:

  • Clinical and Laboratory Screening: Monitoring serum transaminases (liver enzymes), blood counts, and bone marrow cellularity.
  • Etiological Workup: Extensive testing to rule out known causes of hepatitis (Hepatitis A, B, C, E, HIV, CMV, EBV, and Parvovirus B19) and autoimmune markers.
  • Genomics: Whole-exome sequencing (WES) was performed on six of the seven patients to search for underlying genetic triggers.
  • Treatment Protocol: Due to financial constraints, patients were treated with a combination of corticosteroids, IVIg, anabolic steroids, cyclosporine, and thrombopoietin analogues.

Datasets

As a clinical case series, the "dataset" consists of the medical records and genomic data of seven pediatric patients (median age 5.6 years). While small, this cohort provides detailed longitudinal data with a median follow-up of 20 months.

Key Insights and Ideas

  • The IVIg Alternative: The most significant takeaway is that IVIg served as a comparable alternative to ATG. While ATG is the gold standard, the authors found that their cohort's outcomes were similar to those reported in literature for patients receiving the more expensive treatment.
  • Genetic Predisposition: Whole-exome sequencing identified Variants of Uncertain Significance (VUS) in four out of six tested patients. This suggests that HAAA might not be purely "idiopathic" but could be linked to genetic variants that predispose individuals to autoimmunity following a viral or environmental trigger.
  • Clinical Presentation: The hepatitis phase typically precedes the bone marrow failure. In this study, all patients showed bone marrow cellularity of less than 20%, and the majority (6/7) presented with "severe" aplastic anemia, while one had "very severe" disease.

Key Results

  • Survival Rate: 6 out of 7 patients (approx. 85%) survived. One patient unfortunately succumbed to acute liver failure within a week of admission.
  • Remission Status: Of the survivors, two achieved complete remission and four achieved partial remission of pancytopenia (low counts across all blood cell types).
  • Liver Recovery: All surviving patients showed a return to normal serum transaminase levels.
  • Follow-up: The median follow-up period was 20 months (ranging from 6 to 28 months), indicating relatively stable mid-term recovery.

Limitations and Future Work

The primary limitation is the small sample size, which is common in studies of rare diseases but limits the ability to generalize the findings. Additionally, because the patients were treated with a "cocktail" of medications (steroids, cyclosporine, etc.), it is difficult to isolate the exact therapeutic contribution of IVIg alone.

The authors suggest that long-term follow-up is essential to monitor for potential relapses once immunosuppressive therapy is tapered. They also advocate for regular genetic testing in HAAA cases to better understand the link between specific genetic variants and the autoimmune response, which could eventually lead to more personalized "tailored" treatment protocols.

Summary updated

BibTeX
@article{marathe2025hepatitis,
  author = {Madhav Marathe and Sarita Verma and Snehavardhan Pandey and Kannan Subramanian},
  title = {{Hepatitis Associated Severe Aplastic Anemia in Children}},
  journal = {The Indian Journal of Pediatrics},
  year = {2025},
  doi = {10.1007/s12098-025-05718-0},
}

Loading related content...

Figure